In Cell this week: strategies for targeting leukemia with MLL translocations, new Perturb-seq approach, and more.
The team identified gene expression patterns that can determine how severe a patient's systemic sclerosis is and if treatment has been effective.
Guardant360 will be the preferred non-invasive assay for clinical testing of patients at the Lurie Cancer Center, and will be used in various research efforts.
Researchers from Northwestern University uncovered five circulating microRNAs that differentiate patients with very high- and low-risk prostate cancer.
The effort, dubbed the National Resource for Translational and Developmental Proteomics, aims to improve on the technology and train others in its use.
A later change in the protease gene likely enabled the bacterium to cause the invasive infection of bubonic plague.
Using mitochondrial sequences from indigenous individuals in Alaska, researchers explored the genetics of past migrations across the Arctic.
According to the researchers, the system could make top-down approaches more widely shareable as well as improve their applicability to clinical work.
The Lurie Cancer Center leads a trio of partners in the Northwestern Onco-SET research program combining oncology and genomics.
The partners will work to establish the clinical utility of genomic profiling technologies in the development of cancer therapies.
In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.
The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.
A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.
Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.